

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

ANNOUNCEMENT TO THE ASX

IBA RECEIVES STRONG SUPPORT FOR INSTITUTIONAL ENTITLEMENT OFFER

Sydney – 13 March 2009 – IBA Health Group Limited (ASX: IBA) – Australia's largest listed health information technology company is pleased to announce the successful completion of the institutional component of its accelerated non-renounceable pro-rata entitlement offer ("Entitlement Offer"), raising approximately A\$82 million.

The Institutional Entitlement Offer received strong support from IBA's existing institutional shareholders. In addition, strong demand was also shown by institutional shareholders and new investors in the bookbuild of entitlements not taken up.

Executive Chairman and CEO, Gary Cohen, said: "We are pleased with the strong level of support that our existing institutional shareholders have shown, including from our cornerstone shareholder AEP. This is a terrific outcome in current sharemarket conditions and places IBA in a strong capital position to continue to benefit from investment in health IT by governments worldwide."

The Entitlement Offer gives eligible existing shareholders the opportunity to subscribe for 2 new IBA ordinary shares ("New Shares") for every 7 existing IBA shares held at the record date, being 7.00pm Tuesday, 17 March 2009. The price for the New Shares under the Entitlement Offer is A\$0.55 per New Share.

IBA intends to use the proceeds of the Entitlement Offer to retire subordinated borrowings from AEP and other senior borrowings.

New Shares from the Institutional Entitlement Offer are expected to be issued on Friday, 27 March 2009 and will commence trading on the ASX on the same day.

COMMENCEMENT OF THE RETAIL ENTITLEMENT OFFER

Eligible retail shareholders will have the opportunity to participate in the Entitlement Offer at the same offer price and ratio as institutional shareholders. The retail component of the Entitlement Offer ("Retail Entitlement Offer") will open on Friday, 20 March 2009 and is due to close on Monday, 6 April 2009. Eligible retail shareholders wishing to acquire New Shares in the offer will need to complete the Entitlement and Acceptance Form, which is expected to be mailed to them by Thursday, 19 March 2009.

A broker handling fee of 1% will be payable on the Retail Entitlement Offer up to a maximum of \$200 per application.

SHAREHOLDER ENQUIRIES

Retail shareholders who have questions regarding the Retail Entitlement Offer should call the IBA Health Shareholder Information Line on 1300 723 862 (local call cost within Australia) or +61 3 9415 4262 (from outside Australia) at any time from 8.30am to 5.30pm (AEDT) Monday to Friday.

RETAIL ENTITLEMENT OFFER TIMETABLE

Event	Date
Record Date for the Entitlement Offer	7:00pm (AEDT) on 17 March 2009
Mailing of Retail Booklet (incl. Entitlement and Acceptance Form) to Eligible Retail Shareholders	Completed by 19 March 2009
Retail Entitlement Offer opens	20 March 2009*
Retail Entitlement Offer closes	5:00pm on 6 April 2009*
Settlement of the Retail Entitlement Offer	14 April 2009
Issue of New Shares under the Retail Entitlement Offer	15 April 2009
Dispatch of holding statements	16 April 2009
Normal trading of New Shares issued under the Retail Entitlement Offer expected to commence on ASX	16 April 2009**

*This date has been adjusted 1 business day later from IBA's announcement on 12 March 2009.

** This date has been adjusted 1 business day earlier from IBA's announcement on 12 March 2009.

Note: Dates and times are indicative only and subject to change. All times and dates refer to Australia Eastern Daylight Time ("AEDT") while in effect and otherwise to Australian Eastern Standard Time.

This release does not constitute an offer of shares for sale in the United States, or to any person that is or is acting for the account or benefit of any U.S. person (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act") ("U.S. Person"), or in any other jurisdiction in which such an offer would be illegal. The New Shares have not been registered under the Securities Act, and may not be offered or sold in the United States or to or for the account or benefit of U.S. Persons unless the New Shares are registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

This release and its attachments include "forward-looking statements" within the meaning of securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "expect", "intend", "plan", "estimate", "anticipate", "believe", "continue", "objectives", "outlook", "guidance" or other similar words, and include statements regarding certain plans, strategies and objectives of management and expected financial performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside the control of IBA, and its officers, employees, agents or associates, including risks associated with the ability of IBA to raise equity in the Retail Entitlement Offer and other risks described in Annexure B. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward-looking statements and IBA assumes no obligation to update such information.

End of release

For further information contact:

Gary Cohen Executive Chairman & CEO IBA Health Group Limited Phone: +61 2 8251 6700

Email: gary.cohen@ibahealth.com

Stuart Kelly Director Corporate Affairs IBA Health Group Limited Phone: +61 2 8251 6769 Mobile: +61 0 404 082 361

Email: stuart.kelly@ibahealth.com

About IBA Health Group

IBA Health Group Limited (ASX-IBA) is the largest health information technology company listed on the Australian Securities Exchange, and trades globally under the name 'iSOFT'.

IBA builds software applications for healthcare. We work with healthcare professionals to design and build solutions that answer all of the difficult questions posed by today's care delivery challenges. Our solutions act as a catalyst for change, supporting the free exchange of critical information across diverse care settings and participant organisations. We are the leader in the provision of advanced application solutions in modern healthcare economies around the world

Today, more than 13,000 provider organisations in 36 countries across five continents use IBA's solutions to manage patient information and drive improvements in their core processes. The group's sustainable development is delivered through careful planning, in-depth analysis of our market and anticipation of evolving requirements. Our business is driven by the collective talent, experience and commitment of more than 4,000 specialists around the globe, including over 1,700 technology and development professionals.

A global network of IBA subsidiaries, supported by an extensive partner network, provides substantial experience of national healthcare markets. As a result we offer our customers comprehensive knowledge of local market requirements, in terms of culture, language, working practice, healthcare regulation and organisational structure.

For more information on IBA, please visit the company's website at www.ibahealth.com